Text Size

Changes in ocular signs and symptoms in patients switching from bimatoprost-Timolol to tafluprost-Timolol eye drops: An open-label phase IV study

Bourne R.R.A., Kaarniranta K., Lorenz K., Traverso C.E., Vuorinen J., Ropo A.


  • 2019
  • BMJ Open
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Cambridge University Hospitals, Cambridge, United Kingdom; Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Clinica Oculistica Di.N.O.G.M.I., Università di Genova, Ospedale Policlinico San Martino, Genova, Italy; 4Pharma Ltd, Turku, Finland; Global Medical Affairs, Santen Oy, Helsinki, Finland

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group


Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022